Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era

European Journal of Haematology

Volumn 89, Issue 1, 2012, Pages 10-15

  Dimopoulos, Meletios A ^a   Kastritis, Efstathios ^a   Delimpasi, Sossana ^b   Katodritou, Eirini ^c   Hatzimichael, Eleftheria ^d   Kyrtsonis, Marie Christine ^a   Repousis, Panagiotis ^e   Tsirogianni, Maria ^f   Kartasis, Zafiris ^g   Parcharidou, Agapi ^h   Michael, Michalis ⁱ   Michalis, Eurydiki ^j   Tsatalas, Constantinos ^k   Stefanoudaki, Ekaterini ^l   Hatjiharissi, Eudoxia ^c   Gika, Dimitra ^a   Symeonidis, Argiris ^m   Terpos, Evangelos ^a   Zervas, Konstantinos ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c THEAGENIO CANCER HOSPITAL   (Greece)

^d UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^e METAXA CANCER HOSPITAL   (Greece)

^f St Savvas Oncology Hospital   (Greece)

^g General Hospital of Chalkida   (Greece)

^h RED CROSS HOSPITAL   (Greece)

ⁱ NICOSIA GENERAL HOSPITAL   (Cyprus)

^j G GENNIMATAS GENERAL HOSPITAL   (Greece)

^k DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^l AMALIA FLEMING GENERAL HOSPITAL   (Greece)

^m UNIVERSITY OF PATRAS   (Greece)

more..

Author keywords

Bortezomib; Lenalidomide; Prognosis; Renal impairment; Thalidomide

Indexed keywords

ALBUMIN; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE;

AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84862566244     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2012.01784.x     Document Type: Article

References (21)

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-60.
2. Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blade J, Mateos MV, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011;118:4519-29.
3. Ludwig H, Bolejack V, Crowley J, Blade J, Miguel JS, Kyle RA, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol 2010;28:1599-605.
4. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-23.
5. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33.
6. Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clin Proc 2010;85:225-30.
7. Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE, Szubert AJ, et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 2011;118:1231-8.
8. Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002-Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005;23:9219-26.
9. Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksac M, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 2011;118:1239-47.
10. Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009;27:3664-70.
11. Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010;28:2259-66.
12. Ludwig H, Hajek R, Tothova E, Drach J, Adam Z, Labar B, et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2009;113:3435-42.
13. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29-37.
14. Sergi G, De Rui M, Sarti S, Manzato E. Polypharmacy in the elderly: can comprehensive geriatric assessment reduce inappropriate medication use? Drugs Aging 2011;28:509-18.
15. Maione P, Perrone F, Gallo C, Manzione L, Piantedosi F, Barbera S, et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 2005;23:6865-72.
16. Freyer G, Geay JF, Touzet S, Provencal J, Weber B, Jacquin JP, et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol 2005;16:1795-800.
17. Tucci A, Ferrari S, Bottelli C, Borlenghi E, Drera M, Rossi G. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer 2009;115:4547-53.
18. Hurria A. Incorporation of geriatric principles in oncology clinical trials. J Clin Oncol 2007;25:5350-1.
19. Rodin MB, Mohile SG. A practical approach to geriatric assessment in oncology. J Clin Oncol 2007;25:1936-44.
20. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007;25:1824-31.
21. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011;29:3457-65.